产品说明书

Tobramycin

Print
Chemical Structure| 32986-56-4 同义名 : 托普霉素 ;Nebramycin Factor 6;Deoxykanamycin B;NSC 180514;Gernebcin;Distobram
CAS号 : 32986-56-4
货号 : A976001
分子式 : C18H37N5O9
纯度 : ≥900ug/mg
分子量 : 467.514
MDL号 : MFCD00077885
存储条件：

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 2 mg/mL(4.28 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 100 mg/mL(213.9 mM)
动物实验配方：
生物活性
描述 Tobramycin is a new aminoglycoside antibiotic with a broad antibacterial spectrum in vitro, and pharmacokinetic properties similar to those for gentamicin. Like other aminoglycoside antibiotics, tobramycin is active in vitro in low concentrations against Staphylococcus aureus. The sensitivity of P. aeruginosa to tobramycin is influenced by the magnesium, and calcium content of the culture media whilst that of all species is reduced by sodium ions[2]. Aerosolized tobramycin 100 mg/ml solution delivered higher lung dose compared to tobramycin 40 mg/ml solution[3]. When tilmicosin is used to treat clinical outbreaks of M. gallisepticum in broilers, a dosing scheme of 20 mg tilmicosin/kg BW (body weight) for five successive days seems to be the most recommended scheme[4].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02958514 Dry Eye Syndrome Not Applicable Unknown March 2017 -
NCT01319253 - Completed - United States, Indiana ... 展开 >> Indiana University Indianapolis, Indiana, United States, 46202 收起 <<
NCT02334384 Furunculosis Phase 1 Phase 2 Completed - United States, Virginia ... 展开 >> Sentara Norfolk General Hospital Norfolk, Virginia, United States, 23507 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.14mL

0.43mL

0.21mL

10.69mL

2.14mL

1.07mL

21.39mL

4.28mL

2.14mL
参考文献

[1]Loose M, Naber KG, et al. Urinary concentration and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption. Int J Antimicrob Agents. 2017 Nov 17. pii: S0924-8579(17)30396-5.

[2]Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs. 1976;12(3):166–200

[3]Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs. 1976;12(3):166–200

[4]Garmyn A, Vereecken M, De Gussem K, Depondt W, Haesebrouck F, Martel A. Efficacy of Tylosin and Tilmicosin Against Experimental Mycoplasma gallisepticum Infection in Chickens. Avian Dis. 2019;63(2):359–365